

# Thomas A Waldmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9336275/publications.pdf>

Version: 2024-02-01

451  
papers

47,867  
citations

807

118  
h-index

2071

204  
g-index

458  
all docs

458  
docs citations

458  
times ranked

27943  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure of the human immunoglobulin $\hat{1}/4$ locus: Characterization of embryonic and rearranged J and D genes. <i>Cell</i> , 1981, 27, 583-591.	13.5	978
2	The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. <i>Nature Reviews Immunology</i> , 2006, 6, 595-601.	10.6	959
3	Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. <i>Nature</i> , 1984, 311, 626-631.	13.7	891
4	A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. <i>Nature</i> , 1982, 300, 267-269.	13.7	862
5	IL-15 $\hat{1}$ Recycles and Presents IL-15 In trans to Neighboring Cells. <i>Immunity</i> , 2002, 17, 537-547.	6.6	814
6	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9571-9576.	3.3	810
7	Qualitative Analysis of Immune Function in Patients with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1985, 313, 79-84.	13.9	760
8	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	13.7	759
9	THE MULTIFACETED REGULATION OF INTERLEUKIN-15 EXPRESSION AND THE ROLE OF THIS CYTOKINE IN NK CELL DIFFERENTIATION AND HOST RESPONSE TO INTRACELLULAR PATHOGENS. <i>Annual Review of Immunology</i> , 1999, 17, 19-49.	9.5	662
10	Immunoglobulin-Gene Rearrangements as Unique Clonal Markers in Human Lymphoid Neoplasms. <i>New England Journal of Medicine</i> , 1983, 309, 1593-1599.	13.9	621
11	A humanized antibody that binds to the interleukin 2 receptor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 10029-10033.	3.3	607
12	Regulatory CD56 <sup>bright</sup> natural killer cells mediate immunomodulatory effects of IL-2 $\hat{1}$ -targeted therapy (daclizumab) in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5941-5946.	3.3	588
13	Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1984, 81, 5214-5218.	3.3	578
14	Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 74-82.	0.8	571
15	Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins.. <i>Journal of Clinical Investigation</i> , 1983, 71, 301-313.	3.9	564
16	Immunotherapy: past, present and future. <i>Nature Medicine</i> , 2003, 9, 269-277.	15.2	540
17	Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1981, 78, 7096-7100.	3.3	528
18	IL-15 enhances their vivoantitumor activity of tumor-reactive CD8+T Cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1969-1974.	3.3	499

#	ARTICLE	IF	CITATIONS
19	Expression of interleukin 2 receptors on activated human B cells.. Journal of Experimental Medicine, 1984, 160, 1450-1466.	4.2	478
20	Dynamic, yet structured: The cell membrane three decades after the Singer&Nicolson model. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8053-8058.	3.3	472
21	The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science, 1986, 232, 727-732.	6.0	462
22	Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 21, 723-737.	7.7	460
23	Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 9694-9698.	3.3	435
24	A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature, 1989, 339, 394-397.	13.7	435
25	IL-15: A Pleiotropic Cytokine with Diverse Receptor/Signaling Pathways Whose Expression Is Controlled at Multiple Levels. Immunity, 1996, 4, 329-336.	6.6	425
26	Impaired Synthesis of Polyclonal (Non-Paraprotein) Immunoglobulins by Circulating Lymphocytes from Patients with Multiple Myeloma. New England Journal of Medicine, 1975, 293, 887-892.	13.9	424
27	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. Journal of Clinical Oncology, 2000, 18, 1622-1636.	0.8	416
28	The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4940-4944.	3.3	405
29	IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 11445-11450.	3.3	400
30	A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4935-4939.	3.3	379
31	Clustered arrangement of immunoglobulin Î» constant region genes in man. Nature, 1981, 294, 536-540.	13.7	378
32	Rearrangements of Genes for the Antigen Receptor on T Cells as Markers of Lineage and Clonality in Human Lymphoid Neoplasms. New England Journal of Medicine, 1985, 313, 776-783.	13.9	363
33	Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature, 1984, 312, 641-643.	13.7	361
34	Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 4522-4526.	3.3	354
35	Monoclonal antibodies in diagnosis and therapy. Science, 1991, 252, 1657-1662.	6.0	353
36	Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature, 2011, 471, 220-224.	13.7	350

#	ARTICLE	IF	CITATIONS
37	Human immunoglobulin $\lambda$ light-chain genes are deleted or rearranged in $\lambda$ -producing B cells. <i>Nature</i> , 1981, 290, 368-372.	13.7	342
38	The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 10128-10132.	3.3	330
39	Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. <i>Nature</i> , 1998, 391, 700-703.	13.7	330
40	The Multi-Subunit Interleukin-2 Receptor. <i>Annual Review of Biochemistry</i> , 1989, 58, 875-905.	5.0	327
41	Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon $\beta$ . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8705-8708.	3.3	326
42	Cytokines in the Treatment of Cancer. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 6-21.	0.5	315
43	Cytokines in Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028472.	2.3	305
44	Interleukin-15 biology and its therapeutic implications in cancer. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 35-41.	4.0	301
45	Superior T memory stem cell persistence supports long-lived T cell memory. <i>Journal of Clinical Investigation</i> , 2013, 123, 594-9.	3.9	287
46	Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7462-7466.	3.3	284
47	THE ROLE OF THE KIDNEY IN THE CATABOLISM OF BENCE JONES PROTEINS AND IMMUNOGLOBULIN FRAGMENTS. <i>Journal of Experimental Medicine</i> , 1967, 126, 207-221.	4.2	276
48	Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 2031-2035.	3.3	268
49	Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 13897-13902.	3.3	268
50	A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. <i>Nature Medicine</i> , 2011, 17, 604-609.	15.2	267
51	Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985, 82, 4230-4234.	3.3	261
52	Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique.A new approach to classification utilizing tumor markers. <i>Cancer</i> , 1977, 40, 2136-2151.	2.0	245
53	The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. <i>Journal of Clinical Investigation</i> , 1972, 51, 2916-2927.	3.9	245
54	Human immunoglobulin D segments encoded in tandem multigenic families. <i>Nature</i> , 1981, 294, 631-635.	13.7	233

#	ARTICLE	IF	CITATIONS
55	Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. <i>Blood</i> , 2005, 105, 721-727.	0.6	230
56	Disorders of Suppressor Immunoregulatory Cells in the Pathogenesis of Immunodeficiency and Autoimmunity. <i>Annals of Internal Medicine</i> , 1978, 88, 226.	2.0	227
57	Characterization of the human receptor for T-cell growth factor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1983, 80, 6957-6961.	3.3	221
58	Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative SAzary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor.. <i>Journal of Clinical Investigation</i> , 1984, 73, 1711-1718.	3.9	217
59	Human $\beta$ -chain genes are rearranged in leukaemic T cells and map to the short arm of chromosome 7. <i>Nature</i> , 1985, 316, 549-552.	13.7	212
60	The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 5394-5398.	3.3	211
61	Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotropic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 2897-2902.	3.3	208
62	Lymphoid Blast Crises of Chronic Myelogenous Leukemia Represent Stages in the Development of B-Cell Precursors. <i>New England Journal of Medicine</i> , 1983, 309, 826-831.	13.9	204
63	T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 1996-2000.	3.3	200
64	The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. <i>Cancer</i> , 1974, 34, 1510-1515.	2.0	199
65	Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. <i>New England Journal of Medicine</i> , 2018, 378, 1947-1948.	13.9	185
66	Interleukin-2, Interleukin-15, and Their Receptors. <i>International Reviews of Immunology</i> , 1998, 16, 205-226.	1.5	180
67	Preassociation of IL-15 with IL-15R $\alpha$ -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8 <sup>+</sup> /CD44 <sup>high</sup> T Cells and Its Antitumor Action. <i>Journal of Immunology</i> , 2008, 180, 2099-2106.	0.4	180
68	Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 474-478.	3.3	178
69	Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model. <i>Clinical Cancer Research</i> , 2010, 16, 6019-6028.	3.2	178
70	The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy. <i>Cancer Immunology Research</i> , 2015, 3, 219-227.	1.6	178
71	Separation of human blood monocytes and lymphocytes on a continuous percoll gradient. <i>Journal of Immunological Methods</i> , 1980, 33, 1-9.	0.6	177
72	Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 14444-14449.	3.3	177

#	ARTICLE	IF	CITATIONS
73	Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help. <i>Journal of Immunology</i> , 2005, 175, 112-123.	0.4	177
74	X-Linked Hypogammaglobulinemia and Isolated Growth Hormone Deficiency. <i>New England Journal of Medicine</i> , 1980, 302, 1429-1434.	13.9	176
75	The IL-2/IL-2 receptor system: a target for rational immune intervention. <i>Trends in Immunology</i> , 1993, 14, 264-270.	7.5	174
76	Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3392-3397.	3.3	174
77	The Human Interleukin-2 Receptor: Normal and Abnormal Expression in T Cells and in Leukemias Induced by the Human T-Lymphotropic Retroviruses. <i>Annals of Internal Medicine</i> , 1986, 105, 560.	2.0	173
78	Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF- $\kappa$ B site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 2452-2457.	3.3	168
79	Only high-affinity receptors for interleukin 2 mediate internalization of ligand.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 1463-1466.	3.3	165
80	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. <i>Blood</i> , 2011, 117, 4787-4795.	0.6	165
81	The Value of Serum Tumor Markers in the Staging and Prognosis of Germ Cell Tumors of the Testis. <i>Journal of Urology</i> , 1977, 118, 994-999.	0.2	164
82	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1970-1980.	2.5	164
83	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. <i>Journal of Clinical Oncology</i> , 2019, 37, 677-687.	0.8	162
84	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. <i>Blood</i> , 1999, 94, 3340-3348.	0.6	161
85	Immunodeficiency Disease and Malignancy. <i>Annals of Internal Medicine</i> , 1972, 77, 605.	2.0	161
86	Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 483-9.	4.9	159
87	Polyclonal B-Cell Activators in the Study of the Regulation of Immunoglobulin Synthesis in the Human System. <i>Advances in Immunology</i> , 1982, 32, 1-63.	1.1	158
88	The Suppressor-Cell Network in Cancer. <i>New England Journal of Medicine</i> , 1978, 299, 1281-1284.	13.9	156
89	Characterization of a Suppressor-Cell Leukemia. <i>New England Journal of Medicine</i> , 1978, 298, 66-72.	13.9	156
90	Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. <i>Lancet</i> , The, 1990, 335, 497-500.	6.3	156

#	ARTICLE	IF	CITATIONS
91	The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. <i>Microbes and Infection</i> , 2012, 14, 247-261.	1.0	156
92	The IL-15/IL-15R $\alpha$ on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 588-593.	3.3	155
93	T-Cell Lymphoproliferative Syndrome Associated with Human T-Cell Leukemia/Lymphoma Virus. <i>Annals of Internal Medicine</i> , 1984, 100, 543.	2.0	155
94	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1525-1535.	3.2	153
95	A RANDOMIZED PROSPECTIVE TRIAL OF ANTI-TAC MONOCLONAL ANTIBODY IN HUMAN RENAL TRANSPLANTATION. <i>Transplantation</i> , 1991, 51, 107-112.	0.5	151
96	A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy. <i>Clinical Cancer Research</i> , 2007, 13, 958-964.	3.2	150
97	Lymphatic Drainage Imaging of Breast Cancer in Mice by Micro-Magnetic Resonance Lymphangiography Using a Nano-Size Paramagnetic Contrast Agent. <i>Journal of the National Cancer Institute</i> , 2004, 96, 703-708.	3.0	149
98	Cholesterol-dependent clustering of IL-2R $\alpha$ and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 6013-6018.	3.3	148
99	Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps. <i>Immunity</i> , 2015, 42, 826-838.	6.6	147
100	Variable amplification of immunoglobulin $\lambda$ light-chain genes in human populations. <i>Nature</i> , 1983, 304, 172-174.	13.7	141
101	Gain-of-function <i>CCR4</i> mutations in adult T cell leukemia/lymphoma. <i>Journal of Experimental Medicine</i> , 2014, 211, 2497-2505.	4.2	139
102	Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. <i>Annual Review of Immunology</i> , 2017, 35, 533-550.	9.5	139
103	Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5084-5089.	3.3	135
104	Serum Alpha Fetoprotein and Human Chorionic Gonadotropin in the Diagnosis and Management of Nonseminomatous Germ-Cell Testicular Cancer. <i>New England Journal of Medicine</i> , 1976, 295, 1237-1240.	13.9	133
105	Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. <i>Blood</i> , 2006, 108, 1021-1029.	0.6	131
106	Evidence for a Defect in Switch T Cells in Patients with Immunodeficiency and Hyperimmunoglobulinemia M. <i>New England Journal of Medicine</i> , 1986, 314, 409-413.	13.9	130
107	Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey. <i>Journal of Clinical Immunology</i> , 2007, 27, 1-18.	2.0	130
108	Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: A fluorescence resonance energy transfer study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 13134-13139.	3.3	129

#	ARTICLE	IF	CITATIONS
109	The use of antibodies against the IL-2 receptor in transplantation. <i>Current Opinion in Immunology</i> , 1998, 10, 507-512.	2.4	129
110	The association of polycythemia with a cerebellar hemangioblastoma. <i>American Journal of Medicine</i> , 1961, 31, 318-324.	0.6	128
111	IL-15 as a mediator of CD4 <sup>+</sup> help for CD8 <sup>+</sup> T cell longevity and avoidance of TRAIL-mediated apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5201-5206.	3.3	128
112	Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7513-7518.	3.3	127
113	The Arrangement of Immunoglobulin and T Cell Receptor Genes in Human Lymphoproliferative Disorders. <i>Advances in Immunology</i> , 1987, 40, 247-321.	1.1	124
114	Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15849-15854.	3.3	124
115	IL-15/IL-15R $\alpha$ -mediated avidity maturation of memory CD8 <sup>+</sup> T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15154-15159.	3.3	123
116	Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 3845-3850.	3.3	121
117	Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. <i>Journal of Autoimmunity</i> , 2003, 21, 283-293.	3.0	120
118	Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. <i>Cancer Research</i> , 2002, 62, 1083-6.	0.4	120
119	Discordance of human chorionic gonadotropin and alpha-fetoprotein in testicular teratocarcinomas. <i>Cancer</i> , 1973, 31, 1065-1068.	2.0	119
120	Frequent STAT5B mutations in $\hat{3}$ hepatosplenic T-cell lymphomas. <i>Leukemia</i> , 2014, 28, 2244-2248.	3.3	119
121	IL-15 in the Combination Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 868.	2.2	119
122	IL-2 and IL-15 receptor $\hat{A}$ -subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11082-11087.	3.3	114
123	Normal human B cells display ordered light chain gene rearrangements and deletions.. <i>Journal of Experimental Medicine</i> , 1982, 156, 975-985.	4.2	113
124	Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis. <i>Journal of Cellular Biochemistry</i> , 1991, 46, 302-311.	1.2	112
125	IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10915-E10924.	3.3	112
126	Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. <i>Blood</i> , 2010, 116, 3238-3248.	0.6	111



#	ARTICLE	IF	CITATIONS
127	Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. <i>Magnetic Resonance in Medicine</i> , 2003, 50, 758-766.	1.9	109
128	Testicular Germ-Cell Neoplasms: Recent Advances in Diagnosis and Therapy. <i>Annals of Internal Medicine</i> , 1979, 90, 373.	2.0	108
129	A Double-masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , 2007, 15, 63-70.	1.0	108
130	Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 4215-4218.	3.3	103
131	Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1891-1895.	3.3	102
132	Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 2878-2882.	3.3	100
133	Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the $\beta$ -emitting radionuclide, bismuth 213. <i>Blood</i> , 2002, 100, 208-216.	0.6	100
134	Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 3137-3141.	3.3	99
135	miR-155 augments CD8 <sup>+</sup> T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic $\beta$ cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 476-481.	3.3	99
136	Flow cytometric resonance energy transfer measurements support the association of a 95-kDa peptide termed T27 with the 55-kDa Tac peptide.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 7246-7250.	3.3	98
137	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6187-6192.	3.3	97
138	Human T Cell Lymphotropic Virus Type I Tax Activates IL-15 $\beta$ Gene Expression Through an NF- $\kappa$ B Site. <i>Journal of Immunology</i> , 2001, 166, 2602-2609.	0.4	96
139	The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. <i>Cancer</i> , 1976, 37, 215-219.	2.0	95
140	Ataxia-Telangiectasia: A Multisystem Hereditary Disease with Immunodeficiency, Impaired Organ Maturation, X-Ray Hypersensitivity, and a High Incidence of Neoplasia. <i>Annals of Internal Medicine</i> , 1983, 99, 367.	2.0	94
141	Novel T-Lymphocyte Population in Combined Immunodeficiency with Features of Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 1989, 321, 370-374.	13.9	93
142	Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. <i>Cancer Research</i> , 2003, 63, 271-6.	0.4	93
143	Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 7970-7975.	3.3	92
144	Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin.. <i>Journal of Clinical Investigation</i> , 1990, 86, 2093-2098.	3.9	92

#	ARTICLE	IF	CITATIONS
145	Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. <i>Journal of Clinical Investigation</i> , 1971, 50, 2331-2338.	3.9	91
146	Suppressor Cells in Neoplastic Disease. <i>Journal of the National Cancer Institute</i> , 1978, 61, 5-11.	3.0	90
147	Immunoglobulin and T-cell receptor gene rearrangement and expression in human lymphoid leukemia cells at different stages of maturation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 8759-8763.	3.3	90
148	The Multichain Interleukin-2 Receptor: A Target for Immunotherapy. <i>Annals of Internal Medicine</i> , 1992, 116, 148.	2.0	90
149	Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. <i>Cancer Research</i> , 2003, 63, 6453-7.	0.4	89
150	The Long Signal Peptide Isoform and Its Alternative Processing Direct the Intracellular Trafficking of Interleukin-15. <i>Journal of Biological Chemistry</i> , 2000, 275, 30653-30659.	1.6	88
151	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. <i>Cancer Cell</i> , 2018, 34, 286-297.e10.	7.7	88
152	The Suppressor-Cell Network in Cancer. <i>New England Journal of Medicine</i> , 1978, 299, 1335-1341.	13.9	87
153	Enhanced Chromatid Damage in Blood Lymphocytes After G 2 Phase X Irradiation, a Marker of the Ataxia-Telangiectasia Gene. <i>Journal of the National Cancer Institute</i> , 1990, 82, 1050-1054.	3.0	87
154	Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16619-16624.	3.3	87
155	<i>Pseudomonas</i> exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor.. <i>Journal of Clinical Investigation</i> , 1984, 74, 966-971.	3.9	87
156	Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18648-18653.	3.3	86
157	IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. <i>Cancer Research</i> , 2015, 75, 5187-5193.	0.4	86
158	The IL-2/IL-15 receptor systems: targets for immunotherapy. <i>Journal of Clinical Immunology</i> , 2002, 22, 51-56.	2.0	85
159	Effective Cancer Therapy Through Immunomodulation. <i>Annual Review of Medicine</i> , 2006, 57, 65-81.	5.0	85
160	IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. <i>Blood</i> , 2011, 118, 6845-6848.	0.6	84
161	Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes. <i>Immunity</i> , 2001, 14, 105-110.	6.6	83
162	Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. <i>Oncogene</i> , 2007, 26, 3699-3703.	2.6	83

#	ARTICLE	IF	CITATIONS
163	ITK and IL-15 support two distinct subsets of CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12075-12080.	3.3	82
164	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. Clinical Cancer Research, 2019, 25, 4945-4954.	3.2	82
165	The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8291-8295.	3.3	81
166	High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. Journal of Autoimmunity, 2008, 31, 91-97.	3.0	81
167	Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2â€“dependent adult T-cell leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12480-12485.	3.3	81
168	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2039-46.	3.3	81
169	Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2592-2597.	3.3	80
170	Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation. Clinical Cancer Research, 2004, 10, 7712-7720.	3.2	80
171	Survival adjustment of mature dendritic cells by IL-15. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8662-8667.	3.3	80
172	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood, 2019, 134, 1406-1414.	0.6	80
173	FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood, 2011, 118, 3911-3921.	0.6	79
174	The Biology of IL-15: Implications for Cancer Therapy and the Treatment of Autoimmune Disorders. Journal of Investigative Dermatology Symposium Proceedings, 2013, 16, S28-S30.	0.8	79
175	Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia.. Journal of Clinical Investigation, 1983, 71, 282-295.	3.9	79
176	GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia Tâ€“cell lines. FEBS Journal, 2002, 269, 1199-1208.	0.2	78
177	Molecular Genetic Analysis of Human Lymphoid Neoplasms. Annals of Internal Medicine, 1985, 102, 497.	2.0	77
178	Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. Journal of Experimental Medicine, 2020, 217, .	4.2	77
179	Impaired lymphocyte transformation in intestinal lymphangiectasia: evidence for at least two functionally distinct lymphocyte populations in man. Journal of Clinical Investigation, 1972, 51, 1319-1325.	3.9	77
180	Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14308-14313.	3.3	75

#	ARTICLE	IF	CITATIONS
181	IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities. <i>Cancer Immunology Research</i> , 2017, 5, 929-938.	1.6	75
182	Multichain Interleukin-2 Receptor: A Target for Immunotherapy in Lymphoma. <i>Journal of the National Cancer Institute</i> , 1989, 81, 914-923.	3.0	74
183	Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. <i>Blood</i> , 2009, 113, 4016-4026.	0.6	74
184	The Combination of Zidovudine and Interferon Alpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 40, 287-294.	0.6	71
185	Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. <i>American Journal of Hematology</i> , 2017, 92, 892-901.	2.0	71
186	Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-tac. <i>Annals of Neurology</i> , 1998, 44, 942-947.	2.8	70
187	Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E498-E505.	3.3	70
188	Type I and II insulin-like growth factor receptors on human phytohemagglutinin-activated T lymphocytes. <i>Cellular Immunology</i> , 1987, 109, 318-331.	1.4	69
189	Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. <i>Blood</i> , 2003, 102, 284-288.	0.6	69
190	Preclinical and phase I clinical trial of blockade of IL-15 using M1 monoclonal antibody in T cell large granular lymphocyte leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 401-406.	3.3	69
191	The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. <i>Arthritis Research</i> , 2002, 4, S161.	2.0	68
192	Cytokine receptor signaling is required for the survival of ALK <sup>+</sup> anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3975-3980.	3.3	68
193	CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. <i>Blood</i> , 2011, 117, 1938-1946.	0.6	67
194	Association of intercellular adhesion molecule 1 with the multichain high-affinity interleukin 2 receptor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 7329-7333.	3.3	64
195	A novel solid phase technology for high-throughput gene synthesis. <i>BioTechniques</i> , 2008, 45, 340-343.	0.8	64
196	PROLONGATION OF PRIMATE RENAL ALLOGRAFT SURVIVAL BY ANTI-TAC, AN ANTI-HUMAN IL-2 RECEPTOR MONOCLONAL ANTIBODY. <i>Transplantation</i> , 1989, 47, 55-59.	0.5	63
197	Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.. <i>Journal of Experimental Medicine</i> , 1996, 183, 1587-1602.	4.2	63
198	p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. <i>Blood</i> , 2000, 95, 3939-3944.	0.6	63

#	ARTICLE	IF	CITATIONS
199	Viral Activation of Interleukin-15 (IL-15): Characterization of a Virus-Inducible Element in the IL-15 Promoter Region. <i>Journal of Virology</i> , 2000, 74, 7338-7348.	1.5	63
200	Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia. <i>Cancer Research</i> , 2004, 64, 5825-5829.	0.4	63
201	Anaphylactic Reaction s to Ig A: A Difficult Transfusion Problem. <i>American Journal of Clinical Pathology</i> , 1970, 54, 618-621.	0.4	62
202	Increased serum soluble IL-15 $\pm$ levels in T-cell large granular lymphocyte leukemia. <i>Blood</i> , 2012, 119, 137-143.	0.6	62
203	Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 476-484.	0.6	62
204	Herceptin-Geldanamycin Immunoconjugates. <i>Cancer Research</i> , 2004, 64, 1460-1467.	0.4	61
205	Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cells. <i>Journal of Cell Science</i> , 2008, 121, 627-633.	1.2	61
206	Interleukin-15 in the treatment of cancer. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1689-1701.	1.3	61
207	B CELL, HELPER T CELL, AND SUPPRESSOR T CELL ABNORMALITIES CONTRIBUTE TO DISORDERED IMMUNOGLOBULIN SYNTHESIS IN PATIENTS FOLLOWING BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1982, 33, 184-190.	0.5	60
208	Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15R $\pm$ . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13534-13539.	3.3	60
209	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. <i>Clinical Immunology</i> , 2014, 155, 176-187.	1.4	60
210	Deletional rearrangement in the human T-cell receptor alpha-chain locus.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 8608-8612.	3.3	58
211	Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. <i>Arthritis Research</i> , 2004, 6, 174.	2.0	58
212	IL-15: the role of translational regulation in their expression. <i>Journal of Leukocyte Biology</i> , 1996, 59, 476-480.	1.5	57
213	IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 14559-14564.	3.3	57
214	EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 2514-2522.	3.2	57
215	Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease. <i>Journal of Clinical Immunology</i> , 2013, 33, 586-594.	2.0	57
216	Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the $\pm$ -Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/3 Diabodies. <i>Clinical Cancer Research</i> , 2008, 14, 875-882.	3.2	56

#	ARTICLE	IF	CITATIONS
217	Vaccinia Virus-Based Multivalent H5N1 Avian Influenza Vaccines Adjuvanted with IL-15 Confer Sterile Cross-Clade Protection in Mice. <i>Journal of Immunology</i> , 2009, 182, 3063-3071.	0.4	56
218	Juxtaposition of the T-cell receptor alpha-chain locus (14q11) and a region (14q32) of potential importance in leukemogenesis by a 14;14 translocation in a patient with T-cell chronic lymphocytic leukemia and ataxia-telangiectasia.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 9287-9291.	3.3	55
219	Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. <i>Blood</i> , 2008, 111, 5163-5172.	0.6	55
220	Polyclonal Activation of Human B Lymphocytes by Nocardia Water Soluble Mitogen (NWSM). <i>Immunological Reviews</i> , 1979, 45, 69-92.	2.8	54
221	Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. <i>Cancer</i> , 1981, 47, 328-332.	2.0	54
222	Regulation of IFN Regulatory Factor 4 Expression in Human T Cell Leukemia Virus-I-Transformed T Cells. <i>Journal of Immunology</i> , 2002, 169, 3120-3130.	0.4	53
223	Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. <i>Blood</i> , 2004, 104, 3355-3357.	0.6	52
224	Detection of Lymph Node Involvement in Hematologic Malignancies Using Micromagnetic Resonance Lymphangiography with a Gadolinium-Labeled Dendrimer Nanoparticle. <i>Neoplasia</i> , 2005, 7, 984-991.	2.3	52
225	THE ERYTHROPOIESIS-STIMULATING FACTORS PRODUCED BY TUMORS. <i>Annals of the New York Academy of Sciences</i> , 1968, 149, 509-515.	1.8	50
226	The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 2165-2169.	3.3	50
227	Immunoglobulin genes: Rearrangement and translocation in human lymphoid malignancy. <i>Journal of Clinical Immunology</i> , 1984, 4, 1-11.	2.0	49
228	Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. <i>EMBO Journal</i> , 2011, 30, 627-627.	3.5	48
229	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. <i>Clinical Cancer Research</i> , 2016, 22, 310-318.	3.2	48
230	Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science. <i>Trends in Biotechnology</i> , 1986, 4, 259-264.	4.9	47
231	The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the $\beta$ -Emitter $^{211}\text{At}$ , Provides Effective Radioimmunotherapy for a Murine Model of Leukemia. <i>Cancer Research</i> , 2006, 66, 8227-8232.	0.4	46
232	Augmented IL-15 $\beta$ Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice. <i>Journal of Immunology</i> , 2012, 188, 6156-6164.	0.4	46
233	IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4 <sup>+</sup> T cells for heterosubtypic protection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5676-5681.	3.3	46
234	Corticosteroid-Responsive Intestinal Lymphangiectasia Secondary to an Inflammatory Process. <i>New England Journal of Medicine</i> , 1979, 300, 605-606.	13.9	45

#	ARTICLE	IF	CITATIONS
235	IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends in Molecular Medicine, 2003, 9, 517-521.	3.5	44
236	<sup>90</sup> Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13045-13050.	3.3	44
237	Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood, 2009, 113, 1287-1293.	0.6	43
238	Highly Persistent and Effective Prime/Boost Regimens against Tuberculosis That Use a Multivalent Modified Vaccine Virus Ankara-Based Tuberculosis Vaccine with Interleukin-15 as a Molecular Adjuvant. Vaccine Journal, 2010, 17, 793-801.	3.2	43
239	Polyclonal nature of the intestinal mucosal lymphocyte populations in inflammatory bowel disease. Gastroenterology, 1988, 95, 364-370.	0.6	42
240	Preparation of <sup>211</sup> At-Labeled Humanized Anti-Tac Using <sup>211</sup> At Produced in Disposable Internal and External Bismuth Targets. Nuclear Medicine and Biology, 1998, 25, 89-93.	0.3	42
241	Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines. Journal of the National Cancer Institute, 2000, 92, 1573-1581.	3.0	41
242	Clustering of Class I HLA Oligomers with CD8 and TCR: Three-Dimensional Models Based on Fluorescence Resonance Energy Transfer and Crystallographic Data. Journal of Immunology, 2001, 166, 5078-5086.	0.4	41
243	Retargeted $\beta$ -Emitting Radioimmunotherapy Using <sup>213</sup> Bi 1,4,7,10-Tetraazacyclododecane-N,N $\epsilon^2$ ,N $\epsilon^3$ ,N $\epsilon^4$ -Tetraacetic Acid-Biotin. Clinical Cancer Research, 2004, 10, 3137-3146.	3.2	41
244	Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy. Advances in Immunology, 2006, 90, 83-131.	1.1	41
245	Interleukin-15 and Its Receptor Augment Dendritic Cell Vaccination against the <i>neu</i> Oncogene through the Induction of Antibodies Partially Independent of CD4 Help. Cancer Research, 2010, 70, 1072-1081.	0.4	41
246	In vitro generation of antigen-specific hemolytic plaque-forming cells from human peripheral blood mononuclear cells.. Journal of Experimental Medicine, 1981, 154, 1069-1084.	4.2	40
247	Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced HER-2/NEU activation, receptor expression and proliferation of HER-2-positive malignant cell lines. , 1997, 70, 221-229.		40
248	Preparation and in vivo evaluation of linkers for <sup>211</sup> At labeling of humanized anti-Tac. Nuclear Medicine and Biology, 2001, 28, 845-856.	0.3	40
249	Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14169-14174.	3.3	40
250	A biophysical approach to IL-2 and IL-15 receptor function: Localization, conformation and interactions. Immunology Letters, 2008, 116, 117-125.	1.1	40
251	IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective $\beta$ -chain cytokines, decreases leukemic T-cell viability. Leukemia, 2019, 33, 1243-1255.	3.3	40
252	MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of Interleukin-15: Assay qualification, standardization and statistical analysis. Journal of Immunological Methods, 2009, 348, 83-94.	0.6	39

#	ARTICLE	IF	CITATIONS
253	The Role of the Radioimmunoassay of Serum Alpha-Fetoprotein and Human Chorionic Gonadotropin in the Intensive Chemotherapy and Surgery of Metastatic Testicular Tumors. <i>Journal of Urology</i> , 1978, 119, 759-762.	0.2	38
254	Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30).. <i>Journal of Experimental Medicine</i> , 1980, 151, 257-262.	4.2	38
255	Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. <i>Gastroenterology</i> , 1981, 80, 166-168.	0.6	38
256	Immune Receptors: Targets for Therapy of Leukemia/Lymphoma, Autoimmune Diseases and for the Prevention of Allograft Rejection. <i>Annual Review of Immunology</i> , 1992, 10, 675-704.	9.5	38
257	Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. <i>Blood</i> , 2006, 108, 1007-1012.	0.6	38
258	Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice. <i>Journal of Virology</i> , 2007, 81, 8774-8783.	1.5	38
259	Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. <i>Blood</i> , 2010, 116, 5948-5956.	0.6	38
260	IL-15-dependent CD8 <sup>+</sup> CD122 <sup>+</sup> T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4 <sup>+</sup> T cells. <i>European Journal of Immunology</i> , 2014, 44, 3330-3341.	1.6	38
261	Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1624-1629.	3.3	38
262	Trans-endocytosis of intact IL-15R $\alpha$ -IL-15 complex from presenting cells into NK cells favors signaling for proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 522-531.	3.3	38
263	Activation of Leukemic Pro-Suppressor Cells to Become Suppressor-Effector Cells. <i>New England Journal of Medicine</i> , 1981, 304, 1382-1387.	13.9	37
264	Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. <i>Leukemia Research</i> , 2006, 30, 190-203.	0.4	37
265	Normalization of Antibody Responsiveness in a Patient with Common Variable Hypogammaglobulinemia and HIV Infection. <i>New England Journal of Medicine</i> , 1987, 317, 1516-1520.	13.9	36
266	Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8444-8448.	3.3	36
267	Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. <i>Cancer</i> , 1995, 75, 1598-1607.	2.0	34
268	Antibody-based therapy of leukaemia. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e29.	1.6	34
269	Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. <i>Blood</i> , 2013, 121, 5045-5054.	0.6	34
270	Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. <i>Blood</i> , 2013, 121, 2029-2037.	0.6	34



#	ARTICLE	IF	CITATIONS
271	Successful treatment with acyclovir of an immunodeficient patient infected simultaneously with multiple herpesviruses. <i>American Journal of Medicine</i> , 1981, 70, 882-886.	0.6	32
272	Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. <i>Blood</i> , 2006, 108, 705-710.	0.6	32
273	Activated Clearance of a Biotinylated Macromolecular MRI Contrast Agent from the Blood Pool Using an Avidin Chase. <i>Bioconjugate Chemistry</i> , 2003, 14, 1044-1047.	1.8	31
274	Development of an IL-15â€“autocrine CD8 T-cell leukemia in IL-15â€“transgenic mice requires the cis expression of IL-15RÎ±. <i>Blood</i> , 2011, 117, 4032-4040.	0.6	31
275	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1â€“Associated Adult T-cell Leukemia/Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 35-42.	3.2	31
276	Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5146-5151.	3.3	30
277	Combination therapy for adult T-cell leukemiaâ€“xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. <i>Blood</i> , 2005, 105, 1231-1236.	0.6	30
278	Vaccination with tumor cells expressing IL-15 and IL-15RÎ± inhibits murine breast and prostate cancer. <i>Gene Therapy</i> , 2014, 21, 393-401.	2.3	30
279	Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia. <i>Molecular Cancer</i> , 2016, 15, 15.	7.9	30
280	Targeting the interleukin-15 system in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2585-2588.	6.7	29
281	Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid (DOTA)-biotin. <i>Cancer Research</i> , 2002, 62, 5755-60.	0.4	29
282	Alpha-Fetoprotein and Human Chorionic Gonadotropin the Management of Testicular Tumors. <i>Journal of Urology</i> , 1977, 118, 593-596.	0.2	28
283	Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 3344-3347.	3.3	28
284	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 394-408.	0.9	28
285	Micro-MRI methods to detect renal cysts in mice. <i>Kidney International</i> , 2004, 65, 1511-1516.	2.6	27
286	Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model. <i>Leukemia</i> , 2015, 29, 556-566.	3.3	27
287	Protection by universal influenza vaccine is mediated by memory CD4 T cells. <i>Vaccine</i> , 2018, 36, 4198-4206.	1.7	27
288	Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies. , 2021, 9, e002193.		27

#	ARTICLE	IF	CITATIONS
289	Human B lymphocytes express the p75 component of the interleukin 2 receptor. <i>Leukemia Research</i> , 1990, 14, 263-271.	0.4	25
290	Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18091-18096.	3.3	25
291	p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. <i>Blood</i> , 2000, 95, 3939-3944.	0.6	25
292	<i>Isospora belli</i> enteric infection in patients with human T-cell leukemia virus type I-associated adult T-cell leukemia. <i>American Journal of Medicine</i> , 1988, 85, 435-438.	0.6	24
293	Prospective evaluation of some candidate tumor markers in the diagnosis of pancreatic cancer. <i>Digestive Diseases and Sciences</i> , 1980, 25, 161-172.	1.1	23
294	Characterization of a soluble suppressor of human B cell immunoglobulin biosynthesis produced by a continuous human suppressor T cell line.. <i>Journal of Experimental Medicine</i> , 1981, 154, 156-167.	4.2	23
295	Activators of protein kinase C and 5-azacytidine induce IL-2 receptor expression on human T lymphocytes. <i>Journal of Cellular Biochemistry</i> , 1985, 27, 267-276.	1.2	23
296	IFN Regulatory Factor 4 Participates in the Human T Cell Lymphotropic Virus Type I-Mediated Activation of the IL-15 Receptor $\alpha$ Promoter. <i>Journal of Immunology</i> , 2002, 168, 5667-5674.	0.4	23
297	Identification of a $\beta$ Receptor Antagonist That Prevents Reprogramming of Human Tissue-resident Cytotoxic T Cells by IL15 and IL21. <i>Gastroenterology</i> , 2020, 158, 625-637.e13.	0.6	23
298	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. , 2021, 9, e003388.		23
299	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2022, 139, 1541-1556.	0.6	23
300	Clonality and Lymphoproliferative Lesions. <i>New England Journal of Medicine</i> , 1986, 315, 509-511.	13.9	22
301	IL-15 Expands Unconventional CD8 $\alpha$ NK1.1+ T Cells but Not $\gamma$ 18 $\beta$ 18+ NKT Cells. <i>Journal of Immunology</i> , 2008, 180, 7276-7286.	0.4	22
302	A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. <i>Vaccine</i> , 2009, 27, 2121-2127.	1.7	22
303	Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys. <i>Vaccine</i> , 2010, 28, 7081-7091.	1.7	22
304	IL-21-Driven Neoplasms in SJL Mice Mimic Some Key Features of Human Angioimmunoblastic T-Cell Lymphoma. <i>American Journal of Pathology</i> , 2015, 185, 3102-3114.	1.9	22
305	JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 66-70.	1.6	22
306	IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2R $\alpha$ therapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21120-21130.	3.3	22

#	ARTICLE	IF	CITATIONS
307	Impact of antigenemia on the bioactivity of infused anti-Tac antibody: Implications for dose selection in antibody immunotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 1752-1757.	3.3	21
308	How Does Interleukin 15 Contribute to the Pathogenesis of HTLV Type 1-Associated Myelopathy/Tropical Spastic Paraparesis?. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1717-1722.	0.5	21
309	Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink. <i>Frontiers in Immunology</i> , 2020, 11, 1813.	2.2	21
310	Short Communication: Deletion of the p16INK4A Gene in vivo in Acute Adult T Cell Lymphoma/Leukemia Cells and Methylation of the p16INK4A Promoter in HTLV Type I-Infected T Cell Lines. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 709-713.	0.5	20
311	Preparation and in vivo evaluation of a novel stabilized linker for <sup>211</sup> At labeling of protein. <i>Nuclear Medicine and Biology</i> , 2006, 33, 469-480.	0.3	20
312	Plasmid-Encoded Interleukin-15 Receptor $\alpha$ Enhances Specific Immune Responses Induced by a DNA Vaccine <i>In Vivo</i> . <i>Human Gene Therapy</i> , 2009, 20, 1143-1156.	1.4	20
313	Paracrine and Transpresentation Functions of IL-15 Are Mediated by Diverse Splice Versions of IL-15R $\alpha$ in Human Monocytes and Dendritic Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 40328-40338.	1.6	20
314	Demonstration of delta rec-pseudo J alpha rearrangement with deletion of the delta locus in a human stem-cell leukemia. <i>Journal of Experimental Medicine</i> , 1989, 170, 339-342.	4.2	19
315	OLIGOMERIZATION OF IL-2R $\alpha$ . <i>Cytokine</i> , 2002, 17, 82-90.	1.4	19
316	Interleukin-2 receptor $\alpha$ -directed therapies for cutaneous lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1449-1458.	0.9	19
317	Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the $\beta$ -emitting radionuclides <sup>212</sup> Bi or <sup>211</sup> At. <i>Nuclear Medicine and Biology</i> , 2004, 31, 357-364.	0.3	19
318	Preparation and in vivo evaluation of novel linkers for <sup>211</sup> At labeling of proteins. <i>Nuclear Medicine and Biology</i> , 2004, 31, 1061-1071.	0.3	19
319	IL-15 Serves as a Costimulator in Determining the Activity of Autoreactive CD8 T Cells in an Experimental Mouse Model of Graft-versus-Host-Like Disease. <i>Journal of Immunology</i> , 2008, 181, 1109-1119.	0.4	19
320	A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models. <i>Clinical Cancer Research</i> , 2020, 26, 4093-4106.	3.2	19
321	Immunoglobulin and T Cell Antigen Receptor Gene Arrangements Indicate That the Immune Response in Autoimmune Thyroid Disease Is Polyclonal*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 66, 958-963.	1.8	18
322	DIFFERENTIAL IL-2 RECEPTOR EXPRESSION IN RENAL ALLOGRAFT RECIPIENTS TREATED WITH AN ANTI-IL-2-RECEPTOR ANTIBODY. <i>Transplantation</i> , 1989, 48, 415-420.	0.5	18
323	Inducible Knockout of the Interleukin-2 Receptor $\alpha$ Chain: Expression of the High-Affinity IL-2 Receptor Is Not Required for their <i>In Vitro</i> Growth of HTLV-I-Transformed Cell Lines. <i>Virology</i> , 1997, 237, 209-216.	1.1	18
324	Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance. <i>Frontiers in Immunology</i> , 2021, 12, 657293.	2.2	18

#	ARTICLE	IF	CITATIONS
325	Synthesis and biodistribution study of a new $^{211}\text{At}$ -calix[4]arene complex. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2000, 43, 1219-1225.	0.5	17
326	Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas. <i>Journal of Immunotoxicology</i> , 2008, 5, 235-248.	0.9	17
327	NF- $\kappa$ B-induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	17
328	The interleukin-2 receptor on malignant cells: A target for diagnosis and therapy. <i>Cellular Immunology</i> , 1986, 99, 53-60.	1.4	16
329	USE OF YTTRIUM-90-LABELED ANTI-TAC ANTIBODY IN PRIMATE XENOGRAFT TRANSPLANTATION. <i>Transplantation</i> , 1990, 50, 760-765.	0.5	16
330	The IL-2/IL-2 receptor system: a target for rational immune intervention. <i>Trends in Pharmacological Sciences</i> , 1993, 14, 159-164.	4.0	16
331	USE OF AN ANTIBODY AGAINST THE SOLUBLE INTERLEUKIN 2 RECEPTOR $\alpha$ SUBUNIT CAN MODULATE THE STABILITY AND BIODISTRIBUTION OF INTERLEUKIN-2. <i>Cytokine</i> , 1999, 11, 1065-1075.	1.4	16
332	Colorectal carcinoma rearranges cell surface protein topology and density in CD4+ T cells. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 202-207.	1.0	16
333	Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. <i>Blood</i> , 2012, 120, 1816-1819.	0.6	16
334	Results From a First-in-Class Human Study of BNZa1, a Selective Multicytokine Inhibitor Targeting Members of the Common Gamma ( $\gamma$ ) Family of Cytokines. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 264-273.	1.0	16
335	Differential Effects of IL-2 and IL-15 on Expression of IL-2 Receptor $\alpha$ . <i>Biochemical and Biophysical Research Communications</i> , 2001, 285, 1302-1308.	1.0	15
336	ABCs of Radioisotopes Used for Radioimmunotherapy: $\alpha$ - and $\beta$ -Emitters. <i>Leukemia and Lymphoma</i> , 2003, 44, S107-S113.	0.6	15
337	Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in <i>E. coli</i> with stop codon optimization. <i>Biotechnology Progress</i> , 2012, 28, 497-507.	1.3	15
338	Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. <i>Oncology</i> , 2014, 3, e959321.	2.1	15
339	MHC I Expression Regulates Co-clustering and Mobility of Interleukin-2 and -15 Receptors in T Cells. <i>Biophysical Journal</i> , 2016, 111, 100-112.	0.2	15
340	Alternative and canonical NF- $\kappa$ B pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1437-1448.	1.2	15
341	Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin <sup>®</sup> immunoconjugate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 1025-1028.	1.0	14
342	Improved renal clearance and tumor targeting of $^{99\text{m}}\text{Tc}$ -labeled anti-Tac monoclonal antibody Fab by chemical modifications. <i>Nuclear Medicine and Biology</i> , 2002, 29, 139-146.	0.3	14

#	ARTICLE	IF	CITATIONS
343	Cardiac involvement with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience. <i>Leukemia and Lymphoma</i> , 2008, 49, 439-446.	0.6	14
344	Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia. <i>Retrovirology</i> , 2014, 11, 43.	0.9	14
345	The interaction of interleukin 2 with its receptor in the generation of suppressor T cells in antigen-specific and antigen-nonspecific systems in vitro. <i>Clinical Immunology and Immunopathology</i> , 1989, 52, 447-459.	2.1	13
346	THEMEANDERING45-YEARODYSSEY OF ACLINICALIMMUNOLOGIST. <i>Annual Review of Immunology</i> , 2003, 21, 1-27.	9.5	13
347	Detection of receptor trimers on the cell surface by flow cytometric fluorescence energy homotransfer measurements. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005, 1744, 176-198.	1.9	13
348	A novel model of alternative NF- $\kappa$ B pathway activation in anaplastic large cell lymphoma. <i>Leukemia</i> , 2021, 35, 1976-1989.	3.3	13
349	Modifications in Synthesis Strategy Improve the Yield and Efficacy of Geldanamycin~Herceptin Immunoconjugates. <i>Bioconjugate Chemistry</i> , 2002, 13, 786-791.	1.8	12
350	Neoplasms of Immunoregulatory T Cells in Clinical Investigation. <i>Journal of Investigative Dermatology</i> , 1980, 74, 267-271.	0.3	11
351	Blockade of the interleukin-2 receptor by anti-Tac antibody inhibits the generation of antigen-nonspecific suppressor T cells in vitro.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 6478-6482.	3.3	11
352	A very long-acting IL-15: implications for the immunotherapy of cancer. , 2022, 10, e004104.		11
353	T cell disorders in primary immunodeficiency diseases. <i>Seminars in Immunopathology</i> , 1978, 1, 239-264.	4.0	10
354	PROLONGATION OF GRAFT SURVIVAL IN PRIMATE ALLOGRAFT TRANSPLANTATION BY YTTRIUM-90-LABELED ANTI-TAC IN CONJUNCTION WITH GRANULOCYTE COLONY-STIMULATING FACTOR. <i>Transplantation</i> , 1992, 54, 963-968.	0.5	10
355	Distinct Spatial Relationship of the Interleukin~9 Receptor with Interleukin~2 Receptor and Major Histocompatibility Complex Glycoproteins in Human T Lymphoma Cells. <i>ChemPhysChem</i> , 2014, 15, 3969-3978.	1.0	10
356	Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS). <i>Journal of Clinical Immunology</i> , 2015, 35, 661-667.	2.0	10
357	Phase I dose escalation study of the anti-CD2 monoclonal antibody, sipilizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 1466-1469.	0.6	10
358	Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28980-28991.	3.3	10
359	Fc IgM receptors on human lymphoblastoid B cell lines. <i>European Journal of Immunology</i> , 1978, 8, 274-278.	1.6	9
360	A pre-translational defect in a case of human $\gamma$ 4 heavy chain disease. <i>Molecular Immunology</i> , 1986, 23, 725-732.	1.0	9

#	ARTICLE	IF	CITATIONS
361	Sustained suppression of SHIV89.6P replication in macaques by vaccine-induced CD8+ memory T cells. <i>Aids</i> , 2008, 22, 1739-1748.	1.0	9
362	Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes. <i>PLoS ONE</i> , 2015, 10, e0143001.	1.1	9
363	Clinical trial of a humanized anti-IL-2/IL-15 receptor $\beta^2$ chain in HAM/TSP. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1383-1394.	1.7	9
364	<sup>90</sup> Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 249-261.	0.7	9
365	Blockade of IL-15 Utilizing Bnz-1, a Selective $\beta^3$ -Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial. <i>Blood</i> , 2019, 134, 2835-2835.	0.6	9
366	Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML. <i>Blood</i> , 2012, 120, 894-894.	0.6	9
367	Characteristics of Multiple Myeloma as an Immunodeficiency Disease. , 1980, , 151-169.		8
368	Membrane Potential Distinctly Modulates Mobility and Signaling of IL-2 and IL-15 Receptors in T Cells. <i>Biophysical Journal</i> , 2018, 114, 2473-2482.	0.2	8
369	Immunodeficiency: Immunoregulation and immunogenetics. <i>Clinical Immunology and Immunopathology</i> , 1986, 40, 25-36.	2.1	7
370	The Interleukin-2 Receptor: A Target for Immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 1993, 685, 603-610.	1.8	7
371	CVL for ATL?. <i>Blood</i> , 2013, 121, 6-7.	0.6	7
372	Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases. <i>Molecular Cancer</i> , 2021, 20, 86.	7.9	7
373	The Interleukin-2 Receptor: A Target for Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 1992, 323, 57-66.	0.8	7
374	The Interleukin-2 Receptor on Normal and Malignant Lymphocytes. <i>Advances in Experimental Medicine and Biology</i> , 1987, 213, 129-137.	0.8	7
375	The multichain interleukin-2-receptor: A target for immunotherapy of patients with adult T-cell leukemia, autoimmune disorders and individuals receiving allografts. <i>Journal of Autoimmunity</i> , 1988, 1, 641-653.	3.0	6
376	Lymphokine receptor-directed therapy: A model of immune intervention. <i>Journal of Clinical Immunology</i> , 1990, 10, 19S-29S.	2.0	6
377	Lymphokine receptor-directed therapy: A model for immune intervention in leukemia, autoimmunity, and immunodeficiency. <i>Clinical Immunology and Immunopathology</i> , 1991, 61, S37-S46.	2.1	6
378	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 394-408.	0.9	6

#	ARTICLE	IF	CITATIONS
379	Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1841-1848.	1.4	6
380	Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019, 60, 2062-2066.	0.6	6
381	EGR1 Addiction in Diffuse Large B-cell Lymphoma. <i>Molecular Cancer Research</i> , 2021, 19, 1258-1269.	1.5	6
382	Loss of Cytotoxicity and Gain of Cytokine Production in Murine Tumor-Activated NK Cells. <i>PLoS ONE</i> , 2014, 9, e102793.	1.1	6
383	IL-15 <i>Trans</i> -Presentation Is an Autonomous, Antigen-Independent Process. <i>Journal of Immunology</i> , 2021, 207, 2489-2500.	0.4	6
384	Triple combination of BET plus PI3K and NF- $\kappa$ B inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. <i>Blood Advances</i> , 2022, 6, 2346-2360.	2.5	6
385	Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody. <i>Leukemia</i> , 1998, 12, 982-991.	3.3	5
386	Detection of channel proximity by nanoparticle-assisted delaying of toxin binding; a combined patch-clamp and flow cytometric energy transfer study. <i>European Biophysics Journal</i> , 2005, 34, 127-143.	1.2	5
387	Preclinical Evaluation of an Anti-CD25 Monoclonal Antibody, 7G7/B6, Armed with the $^{90}$ Y-Emitter, Yttrium-90, as a Radioimmunotherapeutic Agent for Treating Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 303-309.	0.7	5
388	A New Domain in the Toll/IL-1R Domain-Containing Adaptor Inducing Interferon- $\gamma$ Factor Protein Amino Terminus Is Important for Tumor Necrosis Factor- $\alpha$ Receptor-Associated Factor 3 Association, Protein Stabilization and Interferon Signaling. <i>Journal of Innate Immunity</i> , 2014, 6, 377-393.	1.8	5
389	Minimum degree of overlap between IL-9R and IL-2R on human T lymphoma cells: A quantitative CLSM and FRET analysis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 1106-1117.	1.1	5
390	Bench-to bedside translation of interleukin-15 for immunotherapy: principles and challenges. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 895-898.	2.4	5
391	Metabolism of Immunoglobulins. <i>Clinical Immunobiology</i> , 1976, , 71-95.	0.1	4
392	Analysis of Human Natural Killer Cell Metabolism. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	4
393	Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. <i>Translational Oncology</i> , 2021, 14, 100913.	1.7	4
394	T Cell Disorders in Primary Immunodeficiency Diseases. , 1979, , 5-30.		4
395	IL15 and Anti- $\alpha$ PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2082-2093.	3.2	4
396	Evidence for Distinct IL-2 Receptors in Induction versus Maintenance of LAK Function. <i>Annals of the New York Academy of Sciences</i> , 1988, 532, 480-481.	1.8	3

#	ARTICLE	IF	CITATIONS
397	1988 presidential address of the clinical immunology society: Clinical immunology is everywhere and nowhere—Strength or weakness?. <i>Clinical Immunology and Immunopathology</i> , 1989, 51, 2-12.	2.1	3
398	A Novel Means of Favorably Tipping the Balance between Cytopathic and Regulatory T Cells. <i>Immunity</i> , 2003, 19, 465-466.	6.6	3
399	Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. <i>Retrovirology</i> , 2015, 12, .	0.9	3
400	NK cells prevent T cell lymphoma development in T cell receptor-transgenic mice. <i>Cellular Immunology</i> , 2020, 352, 104081.	1.4	3
401	A Monoclonal Antibody to the Human Receptor for T Cell Growth Factor. , 1984, , 43-66.		3
402	Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy. <i>Blood</i> , 2011, 118, 2575-2575.	0.6	3
403	Abstract 1332: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20. , 2015, , .		3
404	Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors. , 2019, , .		3
405	[12] Methods for the study of the metabolism of immunoglobulins. <i>Methods in Enzymology</i> , 1985, 116, 201-210.	0.4	2
406	Advances in Diagnosis of Hematologic Malignancies. <i>Hospital Practice (1995)</i> , 1986, 21, 69-77.	0.5	2
407	Transmembrane Signals Mediated by IL-2 and IL-15 Control the Life and Death of Lymphocytes. , 2005, , 97-121.		2
408	Selective Dependence of H2-M3—Restricted CD8 Responses on IL-15. <i>Journal of Immunology</i> , 2012, 188, 2575-2582.	0.4	2
409	Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice. <i>Journal of Immunology</i> , 2021, 207, 1194-1199.	0.4	2
410	Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells. <i>Blood</i> , 2016, 128, 503-503.	0.6	2
411	Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies. <i>Blood</i> , 2019, 134, 1558-1558.	0.6	2
412	Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	0.6	2
413	The proportion of TA, TG, and TM cells in various immunodeficiency and autoimmune disorders. <i>Cellular Immunology</i> , 1983, 80, 105-114.	1.4	1
414	Epitope Blocking: Positive and Negative Effects on the Biodistribution of <sup>125</sup> I-Labeled Anti-Tac Disulfide-stabilized Fv Fragment of Two Antibodies against Different Epitopes of the Circulating Antigen. <i>Japanese Journal of Cancer Research</i> , 1998, 89, 436-444.	1.7	1



#	ARTICLE	IF	CITATIONS
415	The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. <i>Journal of Urology</i> , 2002, 167, 934-937.	0.2	1
416	429. Adenoviral-Mediated Interleukin-15 Receptor- $\alpha$ Gene Therapy of Murine Breast Cancer. <i>Molecular Therapy</i> , 2006, 13, S165.	3.7	1
417	A gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the chemotactic abilities and P13K/AKT activation. <i>Retrovirology</i> , 2015, 12, .	0.9	1
418	Engagement of lymphoma T cell receptors causes accelerated growth and the secretion of an NK cell-inhibitory factor. <i>Cellular Immunology</i> , 2020, 357, 104213.	1.4	1
419	Genetic Rearrangements of Human Immunoglobulin Genes. , 1984, , 75-95.		1
420	Interleukin-15. , 2003, , 478-484.		1
421	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 394-408.	0.9	1
422	Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.. <i>Blood</i> , 2008, 112, 2010-2010.	0.6	1
423	T-T INTERACTIONS IN THE GENERATION OF HUMAN SUPPRESSOR EFFECTOR CELLS IN VITRO. , 1979, , 69-84.		1
424	Role and Molecular Biology of the Interleukin-2-Interleukin-2 Receptor System in Health and Disease. , 1986, , 553-562.		1
425	Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein. <i>PLoS ONE</i> , 2015, 10, e0141141.	1.1	1
426	Human B-Cell Precursor Leukemias. <i>Pathology and Immunopathology Research</i> , 1984, 3, 510-519.	0.8	0
427	A T-cell line with an unusual phenotype. <i>Cancer</i> , 1989, 64, 1859-1866.	2.0	0
428	Organization of the Human Immune System. <i>Dermatologic Clinics</i> , 1990, 8, 593-607.	1.0	0
429	REPLY TO SOCHA AND MOOR-JANKOWSKI. <i>Transplantation</i> , 1991, 52, 181.	0.5	0
430	The Metabolism Branch: An Exemplar of Patient-Oriented Research. <i>Cancer Investigation</i> , 1995, 13, 662-663.	0.6	0
431	67 The Drug CP690550 Inhibits the JAK3/STAT5 Pathway In Vitro and In Vivo. <i>Cytokine</i> , 2007, 39, 19.	1.4	0
432	131 Cytokine responses of naive T-cells requires special permission by accessory cells. <i>Cytokine</i> , 2008, 43, 267.	1.4	0

#	ARTICLE	IF	CITATIONS
433	Immune Regulation. , 0, , 33-44.		0
434	Interleukin-15 â††. , 2017, , .		0
435	Making discoveries in immunology. Human Vaccines and Immunotherapeutics, 2019, 15, 280-282.	1.4	0
436	Disorders of Suppressor T Cells in Immunodeficiency and Malignancy. , 1980, , 381-402.		0
437	Molecular Analysis of the Human Interleukin-2 Receptor. , 1985, , 8-20.		0
438	Interleukin-2 Receptors. , 1985, , 285-300.		0
439	Molecular Cloning and Expression of cDNAs Encoding the Human Interleukin-2 Receptor. , 1985, , 185-195.		0
440	The Multichain Interleukin-2-Receptor: A Target for Immunotherapy of Patients with Adult T-cell Leukemia, Autoimmune Disorders and Individuals Receiving Allografts. , 1989, , 145-157.		0
441	The Multichain Interleukin-2 Receptor: From the Gene to the Bedside. , 1989, , 675-683.		0
442	Disorders of IL-2 Receptor Expression in HTLV-I-Associated Adult T Cell Leukemia. , 1989, , 126-141.		0
443	Adult T-cell Leukemia: Prospects for Immunotherapy. , 1991, , 319-334.		0
444	Abstract 2575: Results from the first-in-human phase I trials of recombinant human Interleukin 15 (rhIL-15) administered as a daily 30 minute intravenous infusion (IVB) for 12 consecutive days or as continuous intravenous infusion (CIV) for 240 hours in patients with refractory metastatic cancers. , 2014, , .		0
445	A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation. Blood, 2014, 124, 3566-3566.	0.6	0
446	Abstract 3936: Frequent gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATLL). , 2015, , .		0
447	Abstract 1596: Phase I trial of recombinant human Interleukin 15 (rhIL-15) administered as continuous intravenous infusion (CIV) for 10 days (240 hours) in patients with refractory metastatic cancers. , 2017, , .		0
448	Abstract LB-A06: Pipeline for High Throughput Analysis of Exosomes in Clinical Biofluids. , 2018, , .		0
449	Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers. , 2019, , .		0
450	Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma. Blood, 2019, 134, 3781-3781.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3052-3052.	0.6	0